Investigational Site Number : 1560012

Chengdu 610041

1 studies enrolling now · 1 studies all time

What they study most

Immunoglobulin G4 Related Disease

Studies at this site

• A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease — Recruiting now